VYYRF Stock Chart & Stats
$0.10
$0.00(0.00%)
At close: 4:00 PM EDT
$0.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $1.03
Previous CloseN/A
Volume10.00K
Average Volume (3M)38.23K
Market Cap
$20.62M
Enterprise Value$14.81M
Total Cash (Recent Filing)$441.87K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta-21.41
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding226,342,350
10 Day Avg. Volume16,801
30 Day Avg. Volume38,230
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue313.62
Enterprise Value/Gross Profit-6.81
Enterprise Value/Ebitda-3.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Revenue GrowthRevenue growth shows early commercial traction and indicates that the company is beginning to convert its barium sulfate and barite focus into sales. Although the base remains small, continued growth could support operating leverage if product adoption and commercialization expand over the next several quarters.
Low LeverageVery low leverage limits the financial burden from debt service and reduces exposure to refinancing pressure. This gives Voyageur greater balance-sheet flexibility than a highly indebted early-stage company, although its ability to fund operations still depends on improving cash generation or securing capital.
Improving Cash BurnThe reduction in operating cash outflow is a constructive efficiency trend, showing that cash consumption has moderated from the prior annual period. Sustaining this improvement would extend financial runway and reduce funding pressure, even though the business remains cash-flow negative and has not reached self-financing.
Bears Say
Severe UnprofitabilityDeeply negative gross profit and a large net loss show that the current revenue base is far below the cost structure required to operate the business. Without substantial improvement in pricing, volume, or operating efficiency, losses may continue to absorb capital and delay sustainable commercialization.
Ongoing Cash ConsumptionNegative operating and free cash flow indicate that operations are consuming cash rather than funding growth internally. This creates continuing financing needs and can constrain investment in product development or commercialization, while the close relationship between cash flow and net loss confirms that losses are materially cash-based.
Capital Base ErosionThe material decline in shareholders' equity signals that ongoing losses are eroding the company's capital base. A thinner equity cushion reduces resilience against further operating setbacks and may increase reliance on future financing, potentially limiting strategic flexibility while profitability remains distant.
Voyageur Pharmaceuticals News
VYYRF FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was $0.01 and its highest was $1.03 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is $20.62M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Nov 02, 2026 which is in 19 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Voyageur Pharmaceuticals released its earnings results on Jul 24, 2026. The company reported -$0.004 earnings per share for the quarter.
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 226,342,350 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Voyageur Pharmaceuticals reported an EPS of -$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in VYYRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.